GlassScriptPhysician profile
Pamela J Hackl
NPI 1134125024
$15,620.99
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,148 · 2020: $2,356 · 2021: $2,509 · 2022: $4,201 · 2023: $2,325 · 2024: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,317 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,316.87 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,016.18 | 2019-2024 | |
| Novo Nordisk INC | $2,154.70 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $1,502.57 | 2019-2024 | Korlym |
| Lilly USA, LLC | $1,297.21 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,184.39 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,014.64 | 2019-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.31 | 2019-2024 | Jardiance, Stiolto Respimat |
| Glaxosmithkline, LLC. | $587.00 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $582.20 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $572.89 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Kowa Pharmaceuticals America, INC. | $344.63 | 2019-2022 | |
| Amarin Pharma, INC. | $303.79 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $198.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $178.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.42 | 2019-2024 | Trintellix |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Hackl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.